Anika Therapeutics, Inc. (ANIK) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CareDx, Inc.

Tactile Systems Technology, Inc.

Cerus Corp.

Pulmonx Corp.

Anika Therapeutics, Inc.

Utah Medical Products, Inc.

CVRx, Inc.

AngioDynamics, Inc.

AVITA Medical, Inc.

Orchestra Biomed Holdings, Inc.

Zynex, Inc.

Why is Anika Therapeutics, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate -214.31% of over the last 5 years

The company has declared Negative results for the last 3 consecutive quarters

NET PROFIT(HY) At USD -8.61 MM has Grown at -86.98%
NET SALES(Q) At USD 28.22 MM has Fallen at -17.87%
RAW MATERIAL COST(Y) Grown by 24.04% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -41.98%, its profits have fallen by -105.9%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -41.98% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Anika Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Anika Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Anika Therapeutics, Inc.

-45.3%

-1.15

53.11%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.29%

EBIT Growth (5y)

-214.31%

EBIT to Interest (avg)

-21.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

0.77

Tax Ratio

18.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.10

EV to EBIT

-3.74

EV to EBITDA

-4.95

EV to Capital Employed

1.15

EV to Sales

0.81

PEG Ratio

Dividend Yield

ROCE (Latest)

-30.70%

ROE (Latest)

-22.47%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

PRE-TAX PROFIT(Q)

At USD -3.97 MM has Grown at 42.49%

NET PROFIT(Q)

At USD -4.65 MM has Grown at 44.26%

-22What is not working for the Company

NET PROFIT(HY)

At USD -8.61 MM has Grown at -86.98%

NET SALES(Q)

At USD 28.22 MM has Fallen at -17.87%

RAW MATERIAL COST(Y)

Grown by 24.04% (YoY

CASH AND EQV(HY)

Lowest at USD 106.54 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.29 times

Here's what is working for Anika Therapeutics, Inc.

Pre-Tax Profit

At USD -3.97 MM has Grown at 42.49%

over average net sales of the previous four periods of USD -6.9 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.65 MM has Grown at 44.26%

over average net sales of the previous four periods of USD -8.34 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Here's what is not working for Anika Therapeutics, Inc.

Net Sales

At USD 28.22 MM has Fallen at -17.87%

over average net sales of the previous four periods of USD 34.36 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 106.54 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 4.29 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 24.04% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales